文献速递哮喘

哮喘患者使用度普利尤单抗与淋巴瘤风险:一项基于人群的队列研究

Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
PubMed 文献 · Eur Respir J · 2025-09-25

该研究纳入2018至2024年美国哮喘患者,比较度普利尤单抗与ICS/LABA治疗者,经倾向评分匹配后发现度普利尤单抗组淋巴瘤风险升高(HR 1.79,95%CI 1.19-2.71),尤其T细胞和NK细胞淋巴瘤(HR 4.58,95%CI 1.82-11.53),但全因死亡率显著降低(HR 0.65,95%CI 0.57-0.74)。

要点

  • 哮喘患者使用度普利尤单抗者淋巴瘤风险升高,尤其T细胞和NK细胞淋巴瘤。
  • 度普利尤单抗组全因死亡率显著低于ICS/LABA组(HR 0.65)。
  • 其他恶性肿瘤发生率两组无显著差异,需长期监测淋巴瘤风险。

核心结论

  • 哮喘患者接受度普利尤单抗治疗与淋巴瘤风险升高相关,尤其T细胞和NK细胞淋巴瘤,但全因死亡率显著降低。

研究设计与样本

  • 基于美国人群的队列研究,纳入2018至2024年启动度普利尤单抗或ICS/LABA治疗的哮喘患者,采用倾向评分匹配平衡基线特征。

主要发现

  • 倾向评分匹配后,度普利尤单抗组淋巴瘤发生54例 versus ICS/LABA组43例,HR 1.79(95%CI 1.19-2.71)。
  • T细胞和NK细胞淋巴瘤发生19例 versus ≤10例,HR 4.58(95%CI 1.82-11.53)。
  • 其他恶性肿瘤发生率两组无显著差异。
  • 度普利尤单抗组全因死亡328例 versus ICS/LABA组793例,HR 0.65(95%CI 0.57-0.74)。

临床怎么用

  • 对哮喘患者使用度普利尤单抗时,应意识到淋巴瘤风险升高,尤其T细胞和NK细胞淋巴瘤,需长期监测。
  • 度普利尤单抗治疗与较低全因死亡率相关,临床决策需权衡获益与淋巴瘤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab is approved for the treatment of atopic dermatitis, asthma, and other allergic diseases. Recent studies suggest that patients with atopic dermatitis receiving dupilumab are at a higher risk of developing cutaneous lymphoma. This study aimed to investigate the risk of lymphoma among patients with asthma receiving dupilumab. METHODS: This population-based cohort study included patients in the United States with asthma who initiated dupilumab or the active comparator (combination therapy with inhaled corticosteroids (ICS) plus long-acting β-agonists (LABA), or ICS/LABA), between 2018 and 2024. Propensity score matching was used to balance baseline characteristics between groups. The primary outcome was new-onset lymphoma, and secondary outcomes included other malignancies and all-cause mortality. RESULTS: A total of 14 936 dupilumab-treated and 734 126 ICS/LABA-treated patients with asthma were included. After propensity score matching, dupilumab-treated patients were found to have a higher risk of lymphoma (54 versus 43 cases, hazard ratio (HR) 1.79, 95% CI 1.19-2.71), especially T-cell and natural killer (NK)-cell lymphomas (19 versus ≤10 cases, HR 4.58, 95% CI 1.82-11.53). There was no significant difference in incidence of other malignant neoplasms. Dupilumab was also associated with significantly lower all-cause mortality (328 versus 793 deaths, HR 0.65, 95% CI 0.57-0.74). CONCLUSIONS: Dupilumab treatment was associated with lower all-cause mortality among patients with asthma, despite increased risk of lymphoma, particularly T-cell and NK-cell lymphomas. These findings highlight the need for long-term surveillance and further research into the immunological mechanisms underlying dupilumab-associated lymphoma in asthma.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ma KS, Brumbaugh B, Saff RR, et al. Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study. Eur Respir J. 2025. PMID: 40537179. doi:10.1183/13993003.00139-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。